NaturoMed Therapeutics, the parent company of Stay Wyld Organics, is a vertically integrated functional and medicinal mushroom company. NaturoMed Therapeutics is currently producing bulk functional mushroom powders at its state of the art facility in BC, Canada and selling functional mushroom products to the retail market throughout North America. The company is committed to improving global mental and physical health through the production and distribution of high-quality Canadian grown organic mushroom products. NaturoMed is excited to announce that construction is well underway for its Health Canada Controlled Substances Dealer’s License to produce Psilocybin. Estimated completion is Q4, 2022. NaturoMed plans to produce Psilocybin once it receives the license. NaturoMed’s lead scientist is currently working on new extraction processes to create medicinal IP.
Similar Posts
How Microdosing and Functional Mushrooms Transformed Alli Schaper’s Health
More people are turning to microdosing and functional mushrooms to improve mood and health, and the Microdosing Collective is here to help
Researchers Discover Therapeutic Potential of Non-Hallucinogenic Psychedelic
Researchers have identified a psychedelic with no hallucinogenic characteristics using a new sensor.
MindMed Conference Call Recap & My THOUGHTS (MMED / MNMD)
Hey guys! Here’s the recap of MindMed’s (MMED / MNMD/ MMQ) Q1 conference call. They added lots of color on their different projects, and provided us with a lot of interesting new information. So, in this episode, we will cover a few topics. These are:
1. MindMed’s Mission
2. Their Talent acquisition
3. The Progress of their different clinical trials
4. The future
Timestamps:
0:00 – Intro
1:59 – MindMed’s Mission
4:36 – MMED’s talent acquisition
7:24 – MindMed’s clinical trial progress
10:48 – Psychiatry department : Project Lucy
14:17 – Addiction department : Project Layla (18MC)
18:33 – Pain department: Project Angie to treat pain card
22:56 – Neurology department: Project Flow using LSD microdosing to treat ADHD
23:43 – MindMed (MMED / MNMD) and its future plans
Enjoy!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #MNMD
Are the Subjective Effects of Psychedelics Necessary for Therapy?
Are the subjective effects – that is, the psychedelic trip itself – fundamental for therapeutic outcomes? New research explores.
Psychedelic Business News Spotlight: April 30, 2021
This week in psychedelic business news: Cybin’s experimental psychedelic takes…
Oregon Psilocybin Advisory Board Proposes Legalizing Just One Species of Psychedelic Fungi
“These fungi pose less potential safety risks to consumers,” says Psilocybin Advisory Board mycologist Jessie Uehling.